Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sotagliflozin
Pharma
FDA expert panel spurns Lexicon's approval bid in type 1 diabetes
An FDA advisory committee voted 11-3 to reject Lexicon's Zynquista as an adjunct medication to insulin for those with type 1 diabetes.
Kevin Dunleavy
Nov 1, 2024 11:24am
Viatris lays out $25M to tackle marketing of Lexicon's Inpefa
Oct 17, 2024 10:17am
In restructuring move, Lexicon to lay off 50% of field force
Aug 13, 2024 3:34pm
Lexicon preps FDA resubmission for diabetes hopeful Zynquista
Mar 12, 2024 7:15am
Lexicon poaches BMS' Tom Garner as new commercial lead
Oct 10, 2023 9:45am
Lexicon finally scores FDA nod for heart failure drug Inpefa
May 30, 2023 9:55am
